Schering-Plough Relief on Partner Earnings
Submitted by BioHealth Investor, 24/7 Wall St.
Schering-Plough Corp. (SGP) is probably breathing a sigh of relief this morning after Merck’s earnings as it is partners with the drug giant on Vytorin and Zetia for cholesterol treatments.
The combined Vytorin & Zetia franchise was noted as having some $5.2 Billion in 2007 annual sales, with some $1.5 Billion being reported in the fourth quarter alone.
Merck (MRK) did disclose some 50 lawsuits over these sales and noted that it is complying and cooperating with investigations. But the good news is that the company’s guidance wasn’t sharply changed.
Continue reading article at 24/7 Wall Street…
Visit 1800blogger to see all of our industry leading blogs.
We don't know every stock and we want to know your thoughts. Register on Biotech Stocks Blog now and get published within minutes. Before posting, it is recommended that you review our posting guidelines.
